Kumar Yogesh, MD
Pulmonary Disease · Dresden, TNNPI 1366430993
Payments from drug & device makers
Across 756 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Boehringer Ingelheim$2K
- AstraZeneca$1K
- Harmony Biosciences LLC$775
- Mylan Specialty L.p.$697
- Novo Nordisk$612
- plus $5K from 31 others
What the payments were for
- Consulting fees$2001%
- Food & beverage$13,18196%
- Education$2862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 173 | $3,044 |
| Boehringer Ingelheim | 92 | $1,665 |
| AstraZeneca | 87 | $1,486 |
| Harmony Biosciences LLC | 29 | $775 |
| Mylan Specialty L.p. | 43 | $697 |
| Novo Nordisk | 29 | $612 |
| Bayer | 17 | $551 |
| Merck | 34 | $457 |
| Novartis | 20 | $341 |
| United Therapeutics Corporation | 18 | $320 |
| Lilly USA, LLC | 21 | $312 |
| Sunovion Pharmaceuticals Inc. | 29 | $304 |
| Insmed, Inc. | 14 | $302 |
| Sanofi | 16 | $293 |
| Johnson & Johnson | 13 | $270 |
| Grifols USA, LLC | 10 | $219 |
| Regeneron Healthcare Solutions, Inc. | 11 | $211 |
| Actelion Pharmaceuticals US, Inc. | 10 | $203 |
| Pfizer | 15 | $186 |
| Teva Pharmaceuticals USA, Inc. | 7 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $142 |
| Genentech USA, Inc. | 8 | $134 |
| Verona Pharma, Inc. | 5 | $127 |
| Electromed, Inc. | 11 | $124 |
| Baxter Healthcare | 5 | $93 |
| AbbVie(2 entities) | 6 | $93 |
| Eisai Inc. | 6 | $91 |
| Intuitive Surgical | 1 | $91 |
| Amgen | 5 | $90 |
| Shield Therapeutics Inc | 3 | $81 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Pulmonx Corporation | 2 | $36 |
| Circassia Inc. | 2 | $33 |
| Viatris Specialty LLC | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$200
How this compares
$13,667 in reported general payments places this provider in the 75th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 58 | $754,184 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 760 | $653,208 |
| OpsumitMacitentan | 28 | $353,984 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 222 | $173,325 |
| Dupixent PenDupilumab | 42 | $159,376 |
| OzempicSemaglutide | 92 | $152,193 |
| FarxigaDapagliflozin Propanediol | 102 | $115,921 |
| Pirfenidone | 29 | $114,456 |
| JardianceEmpagliflozin | 119 | $111,807 |
| MounjaroTirzepatide | 56 | $97,665 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $93,992 |
| TrulicityDulaglutide | 41 | $72,876 |
| EliquisApixaban | 68 | $55,993 |
| RybelsusSemaglutide | 29 | $52,394 |
| Dupixent SyringeDupilumab | 14 | $51,879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Jardiance, Glyxambi, Spiriva Respimat, Combivent Respimat | $1,665 | $1,005,343357 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $3,044 | $719,792877 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $203 | $353,98428 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,486 | $293,287337 claims |
| Novo NordiskOzempic, Rybelsus | $612 | $204,587121 claims |
| Lilly USA, LLCMounjaro, Trulicity | $312 | $170,54297 claims |
| MerckJanumet Xr, Januvia, Janumet | $457 | $100,28781 claims |
| PfizerEliquis | $186 | $55,99368 claims |
| Johnson & JohnsonXarelto | $270 | $37,19139 claims |
| NovartisEntresto | $341 | $35,75027 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $142 | $23,61829 claims |
| AbbVieLinzess | $93 | $12,03823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Dresden
- Fabien MaldonadoNashville$2.5M
- Aaron MilstoneFranklin$2.4M
- John SwisherKnoxville$2.3M
- James TolleNashville$2.3M
- Lisa LancasterNashville$1.6M
- Ivan RobbinsNashville$1.3M
- Clyde SouthwellHendersonville$801K
- Krishnendu BhadraChattanooga$631K
- Eric WeaverKnoxville$492K
- Rajiv DhandKnoxville$426K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.